[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fFhd36EPszxHs2WF4ZHlMhmSWE7PviDpLqbRRByrrnUo":8,"$feN75IBYaQSgWVlIOy9rzbQF_ibAqUUH_gpoZCtUnKVU":55,"$fm9DyNcA4GxU5oXX3TlAkD-xy-oqSRb8rDhe8YpH0wWY":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},61740,868960,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//qToouzd3wNZJDyz176JvWbOwPLYeq3AU.png","王淑倩","浙江大学医学院附属第一医院","甲状腺乳腺外科","副主任医师",29,0,"乳腺癌治疗新选择：TCb-EC+PD-1化疗方案安全用药指南","","https://ystcdn.venuertc.com/venue/AI/b6ffcd85-d1cf-4f7a-849d-1dbddcdbc046.jpg","\n\u003Cdiv class=\"custom-material-container\">\n  \u003Ch2 id=\"material_title\" class=\"custom-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌治疗新选择：TCb-EC+PD-1化疗方案安全用药指南\u003C/h2>\n  \u003Cdiv class=\"custom-subtitle-section custom-bg1\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 TCb-EC+PD-1化疗方案到底是什么？ 🧪\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      TCb-EC+PD-1方案是一种联合用药化疗与免疫治疗的组合，主要包括紫杉醇类、铂类、蒽环类药物（TCb和EC组成部分），加上免疫检查点抑制剂（如PD-1单抗）。这些药品各有分工：化疗药物通过影响癌细胞分裂周期发挥作用，免疫药物则激活人体免疫反应，提高身体识别异常细胞的能力。\u003Cbr>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 使用该方案时，请严格遵循医生制定的用药周期，各药物按规定顺序和剂量配合使用，不可随意增减或替换。需要定期监测体内药物反应，及时沟通用药进展。\n    \u003C/div>\n    \u003Cdiv class=\"custom-case\">\n      \u003Cspan class=\"custom-case-title\">📌 用药案例：\u003C/span>一位54岁女性在首周期TCb-EC化疗时，因血液系统反应，未加用免疫药物，并调整了紫杉醇类药物剂量，展现了化疗过程中的个体差异性。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg2\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 关键药理机制与作用特点 🧬\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      \u003Cb>TCb类：\u003C/b>紫杉醇、铂类（如卡铂），主要抑制肿瘤细胞分裂、促进细胞凋亡。\u003Cbr>\n      \u003Cb>EC类：\u003C/b>蒽环（如多柔比星）、环磷酰胺，协同增加对细胞DNA的损伤。\u003Cbr>\n      \u003Cb>PD-1抑制剂：\u003C/b>干扰免疫检查点，使免疫细胞更好地清除异常细胞。各药物在体内代谢途径和作用靶点不同，合用能提高治疗的协同效应，改善化疗耐药或免疫低反应情况。\n      \u003Cdiv class=\"custom-tip\">💡 \n        使用上述药品时，应注意药物的特异性与总体耐受性，遇到异常反应如发热、皮疹等及时上报。\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg3\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药方法及剂型选择指南 💉\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      各类药品剂型多样：紫杉醇和大部分抗癌药通常为静脉注射制剂，部分辅助药（如升白细胞药、止吐药）可为口服或皮下注射。用药方法严格依照医生设定时间和顺序，一般为轮换或者序贯给药。化疗期间，每次注射需在专业医疗场所进行，辅助用药则通常按天服用。\n      \u003Cbr>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 静脉用药勿自行注射，口服制剂建议于同一时刻每日服用，皮下注射注意无菌操作。遇到剂量变更须由医生调整，不得擅自改动。\n    \u003C/div>\n    \u003Cdiv class=\"custom-case\">\n      \u003Cspan class=\"custom-case-title\">📌 临床经验：\u003C/span>患者在使用升白细胞药物时，由于恢复慢，医生改用口服和皮下注射联合，为降低副反应风险提供了实际操作思路。\n    \u003C/div>\n    \u003Cdiv class=\"custom-tip\">💡 \n      特别提醒：肠溶片或缓释剂型不可嚼碎或掰开，避免影响药效，也有的药物需随餐或空腹服用，请仔细阅读说明书或咨询药师。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg1\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 用药注意事项与常见禁忌 ⛔\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      \u003Cb>重要禁忌：\u003C/b>对紫杉醇类药物及其成分有过敏史者不得使用；免疫抑制剂（如PD-1单抗）有自身免疫疾病史或活动性感染需慎用。肝肾严重功能障碍者应调整化疗用量。孕期和哺乳期妇女避免使用化疗药物，必要时更换方案。\n      \u003Cbr>\n      \u003Cspan class=\"custom-highlight\">需要注意：\u003C/span>\n      \u003Cul class=\"custom-list\">\n        \u003Cli>用药前如有明显过敏或异常反应史，必须主治医生评估后决定是否予以化疗/免疫治疗。\u003C/li>\n        \u003Cli>血液系统异常、不符合化疗启动条件者暂缓免疫治疗，待血象恢复后评估重新启动。\u003C/li>\n        \u003Cli>化疗期间建议远离人群、注意防护，避免感染。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg2\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用和联合用药指导 🔑\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      用药联合时需规避以下典型相互作用：\n      \u003Cul class=\"custom-list\">\n        \u003Cli>紫杉醇类不可与强CYP3A4抑制剂（如某些抗真菌药）合用；否则影响代谢，增加毒性。\u003C/li>\n        \u003Cli>PD-1抑制剂与某些免疫调节剂、糖皮质激素合用时会影响疗效，实在需要，请医疗团队专门评估。\u003C/li>\n        \u003Cli>部分升白细胞药物与化疗周期时间需严格错开；不可在药物浓度高峰期合用，避免白细胞无效升高。\u003C/li>\n        \u003Cli>止吐药部分类型与TCb组药物有酶代谢竞争，建议间隔1小时服用。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 合并服药前，请医生或药师审核全部当前用药清单，每增加一种药品都应逐项检查相互作用可能性。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg3\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应识别与处理方案 💊\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      这类方案相关不良反应较为常见，主要包括：\n      \u003Cul class=\"custom-list\">\n        \u003Cli>化疗药物（紫杉醇、铂类、蒽环）可能导致脱发、恶心、白细胞下降等；免疫药物如PD-1抑制剂易引起疲劳、皮疹、免疫相关反应。\u003C/li>\n        \u003Cli>临床数据显示，TCb-EC方案恶心呕吐发生率约50%，紫杉醇类引发白细胞减少率有30%-60%。PD-1相关免疫不良反应发生率在10%-20%。\u003Csup>[1]\u003C/sup>\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 发现任何异常症状时，第一时间报告医生；短期不适如轻度脱发、轻度恶心可用辅助治疗药物缓解；严重不良反应（如发热、重度白细胞下降、持续皮疹等）务必及时就医，不可拖延。\n    \u003C/div>\n    \u003Cdiv class=\"custom-case\">\n      \u003Cspan class=\"custom-case-title\">📌 用药教训：\u003C/span>一名患者静脉用药首周期后出现粒细胞极低，及时停药并采用升白细胞药物治疗，成功避免了严重感染。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg1\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存方法与药品稳定性 🧬\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      \u003Cb>化疗注射剂：\u003C/b>需冷藏（2-8℃），未稀释前勿暴露高温或阳光直射；开封后应在规定时间内使用，否则丢弃。\u003Cbr>\n      \u003Cb>口服辅助药：\u003C/b>置于室温干燥通风处，避免潮湿或靠近热源。皮下注射制剂同样需低温保存。\n      \u003Cbr>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 家庭保存时可用独立冷藏箱存放注射剂，辅助药品分开存储；药品过期立刻丢弃，不得继续使用。每次取药后记得封口，避免空气氧化影响药效。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg2\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服和过量处理技巧 ⚠️\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      \u003Cul class=\"custom-list\">\n        \u003Cli>未按时服用口服药，可以补服一次；若即将到下次服药时间，跳过漏服，不要双倍剂量。\u003C/li>\n        \u003Cli>静脉化疗如因特殊情况延迟或漏用，必须医生重新安排，绝不能自行补用。\u003C/li>\n        \u003Cli>如出现疑似过量用药（如短期多服、注射剂重复给药），立刻就医，由专业团队处理，可根据药品说明书采取血液净化、对症支持等措施。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"custom-highlight\">特别提醒：\u003C/span> 按照治疗方案服药，不要临时自己增减；如果不确定是否漏服，先咨询医生或药师。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-subtitle-section custom-bg3\">\n    \u003Ch2 class=\"custom-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 特殊人群用药调整 👩‍🎓\u003C/h2>\n    \u003Cdiv class=\"custom-paragraph\">\n      \u003Cul class=\"custom-list\">\n        \u003Cli>老年人化疗耐受力较低，应根据肝肾功能评估调整剂量，更频繁监测血象。\u003C/li>\n        \u003Cli>孕妇、哺乳期女性通常不推荐TCb-EC+PD-1类药物；如无替代方案应全程在专科指导下实施，仔细规避药品对胎儿影响。\u003C/li>\n        \u003Cli>肝肾功能不全者先行评估清除率，必要时减少剂量或延长给药间隔。\u003C/li>\n        \u003Cli>青少年、儿童一般暂不推荐应用该完整方案，特殊情况下须专科论证。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"custom-highlight\">正确做法：\u003C/span> 在有多种药品联合时，务必依据年龄及特殊生理状态调整剂量，用药前评估风险，避免一步到位的标准剂量或固定周期。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-summary-section\">\n    \u003Ch2 class=\"custom-summary-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：安全用药要点小结 💯\u003C/h2>\n    \u003Cdiv class=\"custom-summary-paragraph\">\n      TCb-EC+PD-1方案为肿瘤化疗和免疫治疗联合用药代表，关键在于：严守服药方法、注意药物相互作用、重视不良反应、妥善保存药品和合理处理漏服过量。适合特殊人群需专职医生个体化调整，避免自行用药或调整剂量。\u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-highlight\">最重要提醒：\u003C/span> 每种药品都需要严格遵循说明书和医嘱进行使用，异常反应不可拖延，储存及配伍细节同样关键。合理搭配用药，科学管理副作用，是提高治疗效果和安全性的关键。遇到疑问或突发情况，应立即联系医疗或药学专业人员协助处理。\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-reference-section\">\n    \u003Ch2 class=\"custom-reference-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 📚\u003C/h2>\n    \u003Cul class=\"custom-reference-list\">\n      \u003Cli>\n        Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., ... & Emens, L. A. (2020). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 382(6), 599-609. DOI: 10.1056/NEJMoa1909628\n      \u003C/li>\n      \u003Cli>\n        Cortes, J., Cescon, D. W., Rugo, H. S., et al. (2020). Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Advanced or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): a Randomised, Placebo-controlled, Phase 3 Clinical Trial. \u003Ci>Lancet\u003C/i>, 396(10265), 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9\n      \u003C/li>\n      \u003Cli>\n        National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. NCCN.org.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.custom-material-container {\n  font-family: \"Segoe UI\", \"Arial\", \"PingFang SC\", \"Helvetica Neue\", sans-serif;\n  background: #fbfcfd;\n  color: #212226;\n  max-width: 850px;\n  margin: 36px auto 40px auto;\n  padding: 32px 28px 18px 28px;\n  border-radius: 18px;\n  box-shadow: 0 6px 18px 0 rgba(41,60,87,0.06);\n  border: 1px solid #f1f3f5;\n}\n\n.custom-title {\n  font-size: 2.4em;\n  color: #234a78;\n  text-align: center;\n  font-weight: bold;\n  margin-bottom: 32px;\n  padding-bottom: 10px;\n  border-bottom: 2px solid #e2e6ea;\n  letter-spacing: 2px;\n}\n\n.custom-subtitle-section {\n  margin-top: 32px;\n  margin-bottom: 36px;\n  padding: 30px 23px 24px 23px;\n  border-radius: 16px;\n  box-shadow: 0 3px 12px 0 rgba(41,60,87,0.05);\n  position: relative;\n}\n\n.custom-bg1 {\n  background: linear-gradient(120deg, #e9f8ff 0%, #f5fcff 100%);\n}\n\n.custom-bg2 {\n  background: linear-gradient(120deg, #f7f7fa 0%, #eaf7ee 100%);\n}\n\n.custom-bg3 {\n  background: linear-gradient(120deg, #fff7ea 0%, #faf9ee 100%);\n}\n\n.custom-subtitle {\n  font-size: 1.55em;\n  color: #1f6572;\n  font-weight: 600;\n  margin-bottom: 16px;\n  margin-left: 6px;\n  letter-spacing: 1px;\n}\n\n.custom-paragraph {\n  font-size: 1.11em;\n  line-height: 2.08em;\n  color: #243148;\n  margin-bottom: 8px;\n  margin-left: 3px;\n  padding-bottom: 2px;\n}\n\n.custom-case {\n  background: #edf0fa;\n  color: #33405a;\n  font-size: 1em;\n  margin: 14px 0 0 0;\n  padding: 12px 15px 10px 13px;\n  border-left: 6px solid #5073b8;\n  border-radius: 8px;\n  box-shadow: 0 2px 6px 0 rgba(41,60,87,0.04);\n}\n\n.custom-case-title {\n  font-weight: bold;\n  color: #365484;\n  margin-right: 4px;\n}\n\n.custom-tip {\n  background: #f3fbf6;\n  border-left: 4px solid #91c8a2;\n  display: block;\n  margin: 18px 0 4px 0;\n  padding: 10px 16px 8px 13px;\n  color: #206c4c;\n  font-size: 1em;\n  border-radius: 8px;\n}\n\n.custom-highlight {\n  color: #0e799e;\n  font-weight: 600;\n}\n\n.custom-list {\n  padding-left: 30px;\n  margin: 6px 0 4px 0;\n  font-size: 1em;\n}\n\n.custom-list li {\n  margin-bottom: 6px;\n  line-height: 1.85em;\n}\n\n.custom-summary-section {\n  background: linear-gradient(90deg, #f4f8ff 0%, #eaf6f7 100%);\n  border-radius: 16px;\n  margin: 36px 0;\n  padding: 26px 22px 17px 22px;\n  box-shadow: 0 2px 8px 0 rgba(35, 74, 120, 0.04);\n}\n\n.custom-summary-title {\n  font-size: 1.3em;\n  font-weight: 600;\n  color: #234a78;\n  margin-bottom: 11px;\n}\n\n.custom-summary-paragraph {\n  font-size: 1.11em;\n  color: #2e4a68;\n  line-height: 2em;\n}\n\n.custom-reference-section {\n  background: #f8f7f4;\n  border-radius: 14px;\n  margin-top: 26px;\n  padding: 18px 14px 12px 16px;\n  box-shadow: 0 1px 7px 0 rgba(33,68,116,0.06);\n}\n\n.custom-reference-title {\n  font-size: 1.23em;\n  color: #556793;\n  font-weight: 600;\n  margin-bottom: 7px;\n}\n\n.custom-reference-list {\n  font-size: 1em;\n  color: #537080;\n  padding-left: 18px;\n}\n\n.custom-reference-list li {\n  margin-bottom: 8px;\n  line-height: 1.66em;\n}\n\n@media (max-width: 1000px) {\n  .custom-material-container {\n    max-width: 98%;\n    padding: 18px 5px;\n  }\n\n  .custom-title {font-size:2em;margin-bottom:20px;}\n  .custom-subtitle-section {padding:18px 5px;}\n}\n\u003C/style>\n\n","\n\u003Cdiv class=\"custom-material-container\">\n  \u003Ch2 id=\"material_title\" class=\"custom-title\" style=\"color",591,"2025-08-21 15:06:50","乳腺癌, TCb-EC, PD-1化疗, 安全用药, 化疗方案","探索TCb-EC+PD-1化疗方案的安全用药指南，了解其药理机制、不良反应和用药注意事项。适合乳腺癌患者及其家属，助力安全有效治疗。","2025-08-23 12:14:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]